Codexis (NASDAQ: CDXS) and Repros Therapeutics (NASDAQ:RPRX) are both small-cap industrial products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Valuation and Earnings

This table compares Codexis and Repros Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Codexis $43.16 million 5.07 -$15.16 million ($0.41) -12.93
Repros Therapeutics N/A N/A -$18.37 million ($0.73) -0.43

Codexis has higher revenue and earnings than Repros Therapeutics. Codexis is trading at a lower price-to-earnings ratio than Repros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Codexis has a beta of -1.43, meaning that its stock price is 243% less volatile than the S&P 500. Comparatively, Repros Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.

Institutional & Insider Ownership

55.6% of Codexis shares are owned by institutional investors. Comparatively, 17.2% of Repros Therapeutics shares are owned by institutional investors. 9.8% of Codexis shares are owned by insiders. Comparatively, 7.4% of Repros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Codexis and Repros Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Codexis -40.70% -83.39% -45.44%
Repros Therapeutics -49,564.86% -276.50% -195.41%

Analyst Ratings

This is a summary of current ratings and recommmendations for Codexis and Repros Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codexis 0 1 3 0 2.75
Repros Therapeutics 0 1 1 0 2.50

Codexis presently has a consensus target price of $6.94, suggesting a potential upside of 30.90%. Repros Therapeutics has a consensus target price of $1.50, suggesting a potential upside of 377.71%. Given Repros Therapeutics’ higher probable upside, analysts plainly believe Repros Therapeutics is more favorable than Codexis.

Summary

Codexis beats Repros Therapeutics on 10 of the 12 factors compared between the two stocks.

Codexis Company Profile

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.